Control of Apoptosis in Cancer by Survivin
Control of Apoptosis in Cancer by Survivin
批准号:
9305689
负责人:
Dario C Altieri
金额:
$22.8万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1998
资助国家:
美国
项目状态:
已结题
起止时间:
1998-07-01 至 2017-05-31
关键词:
ActinsAffectApoptosisBasement membraneBioenergeticsCancer PatientCell CycleCell PolarityCell RespirationCessation of lifeChemotaxisClinicCompetenceComplexCytoskeletonDataDiseaseDistantDrug resistanceEnergy-Generating ResourcesExposure toExtracellular MatrixFocal AdhesionsFollow-Up StudiesGlycolysisHeterogeneityHomeostasisImpairmentInvadedKineticsKnowledgeMalignant NeoplasmsMalignant neoplasm of prostateMapsMembraneMetabolicMetabolismMitochondriaModelingMovementNeoplasm MetastasisOncogenesOrganOrganellesOutcomeOxidative PhosphorylationOxygenParentsPathway interactionsPeer ReviewPhosphorylationPhosphotransferasesPlayProcessProteolysisPublishingQuality ControlRecruitment ActivityRegulationReview LiteratureRoleShapesSignal TransductionStimulusStressTissuesTumor Cell InvasionTumor Cell MigrationWarburg EffectWorkcell motilitycell transformationexperimental studygenome-widein vivometastatic processneoplastic cellnew therapeutic targetnovelorganelle movementparkin gene/proteinpreventprogramspublic health relevancereceptorresponsesmall hairpin RNAspatiotemporalstemnesssurvivintherapeutic targettraffickingtraittumortumor heterogeneitytumor metabolismtumorigenesis
中文摘要
项目总结
英文摘要
PROJECT SUMMARY
One of the hallmarks of cancer is the reprogramming of metabolism from oxidative phosphorylation that takes
place in mitochondria to glycolysis, regardless of oxygen availability. This so-called “Warburg effect” is an
important disease driver and hallmark of poor outcome. However, it is now clear that there is greater
complexity in tumor metabolism, as mitochondria continue to play an important role in the bioenergetics of
transformed cells, and fuel key cancer traits of proliferation, drug resistance, stemness and invasion. Work
supported by CA78801 demonstrated that a pool of the cancer gene, survivin present in mitochondria of tumor
cells maintained oxidative phosphorylation metabolism. In turn, energy produced via this pathway enabled the
subcellular movement of mitochondria to the cortical cytoskeleton of tumor cells, fueling membrane
lamellipodia dynamics, turnover of focal adhesion complexes, and sustained phosphorylation of cell motility
kinases. Together, this led to heightened tumor chemotaxis, invasion and metastasis, in vivo. Published in the
peer-reviewed literature (Sci Signal 8:389, 2015;; PNAS 112:8638, 2015), and discussed in three invited review
articles (Pharmacol Rev 102:42, 2015;; Cell Cycle 14:20, 2015;; Clin Cancer Res 22:540, 2016), these results
supported a model of spatiotemporal mitochondrial bioenergetics as a requirement of tumor cell motility,
invasion and metastasis. In follow-up studies, we have now found that changes in mitochondrial size and
shape, known as dynamics, as well as mechanisms of organelle quality control, such as mitophagy, are
essential regulators of this pathway. Specifically, conditions that impair mitochondrial fusion, promote
exaggerated mitochondrial fragmentation (fission), or activate mitophagy suppress mitochondrial trafficking and
block tumor cell motility. Therefore, the hypothesis that organelle dynamics and quality control regulate
spatiotemporal mitochondrial bioenergetics and metastatic competence can be formulated, and will constitute
the focus of the present revision application. In continuity with the objectives of CA78810, the first specific aim
will elucidate how mitochondrial fusion and fission regulate organelle movements, membrane-actin dynamics
and the machinery of tumor cell motility. The second specific aim will focus on Parkin-dependent and –
independent mitophagy, and a novel role of the FUNDC2 molecule as novel “metastasis suppressors”,
regulating mitochondrial recruitment to the cortical cytoskeleton and the bioenergetics of tumor cell invasion.
As dynamics and quality control are the primary effectors of mitochondrial heterogeneity, these studies are an
ideal match to the objective of the PQ5 Program, will conclusively answer its overarching question of how does
mitochondrial heterogeneity influence tumorigenesis or progression, and uncover actionable therapeutic
targets to limit disease dissemination in the clinic.
期刊论文(22)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
--
发表时间:
2003
期刊:
Progress in cell cycle research
影响因子:
--
作者:
[D. Altieri]
通讯作者:
D. Altieri
DOI:
10.4161/cc.8.17.9457
发表时间:
2009-09-01
期刊:
Cell cycle (Georgetown, Tex.)
影响因子:
--
作者:
[Guha M, Altieri DC]
通讯作者:
Altieri DC
Profiles and legacies in cancer biology.
癌症生物学的概况和遗产。
DOI:
10.4161/cbt.3.5.811
发表时间:
2004
期刊:
Cancer biology & therapy
影响因子:
3.6
作者:
[Altieri,DarioC]
通讯作者:
Altieri,DarioC
DOI:
10.1158/0008-5472.can-11-4035
发表时间:
2012-07-01
期刊:
Cancer research
影响因子:
11.2
作者:
[Lopergolo A, Tavecchio M, Lisanti S, Ghosh JC, Dohi T, Faversani A, Vaira V, Bosari S, Tanigawa N, Delia D, Kossenkov AV, Showe LC, Altieri DC]
通讯作者:
Altieri DC
Survivin expression in mouse skin prevents papilloma regression and promotes chemical-induced tumor progression.
小鼠皮肤中生存素的表达可防止乳头状瘤消退并促进化学诱导的肿瘤进展。
DOI:
--
发表时间:
2003
期刊:
Cancer research.
影响因子:
--
作者:
[Allen,SarahM, Florell,ScottR, Hanks,AdrianneN, Alexander,April, Diedrich,MiyoungJ, Altieri,DarioC, Grossman,Douglas]
通讯作者:
Grossman,Douglas
共 12 条
Augmenting T-cell immunotherapy outcomes in blood and solid tumor microenvironment in ART-suppressed HIV infection (immune/microenvironment)
-
批准号:10620011
-
项目类别:
-
资助金额:$12.42万
-
财政年份:2022
-
负责人:Dario C Altieri
-
依托单位:
A First-in-Human Phase I Clinical Trial of Mitochondrial-Targeted Hsp90 Inhibitor, Gamitrinib
-
批准号:10472429
-
项目类别:
-
资助金额:$31.63万
-
财政年份:2021
-
负责人:Dario C Altieri
-
依托单位:
A First-in-Human Phase I Clinical Trial of Mitochondrial-Targeted Hsp90 Inhibitor, Gamitrinib
-
批准号:9668658
-
项目类别:
-
资助金额:$41.03万
-
财政年份:2021
-
负责人:Dario C Altieri
-
依托单位:
Tumor Plasticity
-
批准号:10474434
-
项目类别:
-
资助金额:$111.72万
-
财政年份:2017
-
负责人:Dario C Altieri
-
依托单位:
Tumor Plasticity
-
批准号:9767084
-
项目类别:
-
资助金额:$110.42万
-
财政年份:2017
-
负责人:Dario C Altieri
-
依托单位:
Tumor Plasticity
-
批准号:10248385
-
项目类别:
-
资助金额:$114.0万
-
财政年份:2017
-
负责人:Dario C Altieri
-
依托单位:
Tumor Plasticity
-
批准号:10684678
-
项目类别:
-
资助金额:$111.72万
-
财政年份:2017
-
负责人:Dario C Altieri
-
依托单位:
Tumor Plasticity
-
批准号:9538612
-
项目类别:
-
资助金额:$114.0万
-
财政年份:2017
-
负责人:Dario C Altieri
-
依托单位:
Molecular and Cellular Oncogenesis
-
批准号:8690263
-
项目类别:
-
资助金额:$3.77万
-
财政年份:2014
-
负责人:Dario C Altieri
-
依托单位:
Planning and Evaluation
-
批准号:8690274
-
项目类别:
-
资助金额:$3.53万
-
财政年份:2014
-
负责人:Dario C Altieri
-
依托单位:
(PQC2) Plasticity Of The.PI3K Network In Early Dormancy
-
批准号:8791730
-
项目类别:
-
资助金额:$38.39万
-
财政年份:2014
-
负责人:Dario C Altieri
-
依托单位:
Bioinformatics Shared Resources
-
批准号:8690292
-
项目类别:
-
资助金额:$22.14万
-
财政年份:2014
-
负责人:Dario C Altieri
-
依托单位:
Genomics
-
批准号:8932921
-
项目类别:
-
资助金额:$21.48万
-
财政年份:2014
-
负责人:Dario C Altieri
-
依托单位:
Gene Expression
-
批准号:8689270
-
项目类别:
-
资助金额:$4.18万
-
财政年份:2014
-
负责人:Dario C Altieri
-
依托单位:
Molecular Screening Shared Resource
-
批准号:8932922
-
项目类别:
-
资助金额:$18.81万
-
财政年份:2014
-
负责人:Dario C Altieri
-
依托单位:
IMAGING SHARED RESOURCE
-
批准号:8689269
-
项目类别:
-
资助金额:$7.59万
-
财政年份:2014
-
负责人:Dario C Altieri
-
依托单位:
Developmental Funds
-
批准号:8690275
-
项目类别:
-
资助金额:$44.68万
-
财政年份:2014
-
负责人:Dario C Altieri
-
依托单位:
Proteomics Shared Resource
-
批准号:8932923
-
项目类别:
-
资助金额:$18.74万
-
财政年份:2014
-
负责人:Dario C Altieri
-
依托单位:
Animal Facility Shared Resources
-
批准号:8690265
-
项目类别:
-
资助金额:$25.87万
-
财政年份:2014
-
负责人:Dario C Altieri
-
依托单位:
(PQC2) Plasticity Of The.PI3K Network In Early Dormancy
-
批准号:9112948
-
项目类别:
-
资助金额:$39.43万
-
财政年份:2014
-
负责人:Dario C Altieri
-
依托单位:
海外基金